Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, child: Pineal parenchymal tumors
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-20 of 20 for your search:
Start Over
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 25
Sponsor: NCI, Other
Protocol IDs: 09-361, P01CA021239, NCT01063114
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI, Other
Protocol IDs: ACNS1123, NCI-2012-01967, CDR0000734032, U10CA098543, COG-ACNS1123, NCT01602666
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RADBEV, NCI-2011-01149, NCT00756340
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 22
Sponsor: Pharmaceutical / Industry
Protocol IDs: 07-098, NCT00634231
Photodynamic Therapy (PDT) for Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: 163588-1, NCT01682746
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI, Other
Protocol IDs: PBTC-042, U01CA081457, NCT02255461
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 3 at diagnosis
Sponsor: NCI, Other
Protocol IDs: SJYC07, R01CA154619, NCI-2011-01193, SJCRH-SJYC07, NCT00602667
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 2 to 25
Sponsor: Other
Protocol IDs: 2005P001629, NCT01115777
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Phase: No phase specified
Type: Treatment
Status: Active
Age: 19 months to 20 years
Sponsor: Other
Protocol IDs: PRO08030085, NCT01130077
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Phase: No phase specified
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 2011OC057, MT2011-09C, NCT01505569
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 month to 29 years
Sponsor: Other
Protocol IDs: SC-9006, NCT02015728
Start Over